[Melatonin for children with insomnia]

Ugeskr Laeger. 2018 May 7;180(19):V08170628.
[Article in Danish]


Treatment for insomnia with melatonin (MT) in children and adolescents aged 0-17 years has doubled since 2011. The efficacy and safety profile for MT in children has not been determined. Recent clinical trials indicate, that MT only has a clinical effect on sleep latency, not on total sleep time. Furthermore, it has emerged, that proper sleep hygiene can cure the sleep problem in 50% of the children. Typically, the safety evaluation only entails an unclassified report of adverse events. Two long-term studies investigate and dispel the potential influence of MT on puberty.

Publication types

  • Review

MeSH terms

  • Adolescent
  • Central Nervous System Depressants / administration & dosage
  • Central Nervous System Depressants / adverse effects
  • Central Nervous System Depressants / pharmacokinetics
  • Central Nervous System Depressants / therapeutic use*
  • Child
  • Child, Preschool
  • Humans
  • Melatonin / administration & dosage
  • Melatonin / adverse effects
  • Melatonin / pharmacokinetics
  • Melatonin / therapeutic use*
  • Puberty / drug effects
  • Sleep / drug effects
  • Sleep / physiology
  • Sleep Hygiene
  • Sleep Initiation and Maintenance Disorders / drug therapy*
  • Sleep Latency / drug effects
  • Sleep Wake Disorders / drug therapy


  • Central Nervous System Depressants
  • Melatonin